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Abstract 
Background: Brain derived neurotrophic factor (BDNF) is involved in numerous cognitive 
processes. Since cognitive deficits are a core feature of psychotic disorders, the investigation 
of BDNF levels in psychosis and their correlation with cognition has received increased 
attention. However, there are no studies investigating BDNF levels in individuals with an at-
risk mental state (ARMS) for psychosis. Hence, the aims of the present study were: (1) 
assessing peripheral BDNF levels across different (potential) stages of psychosis; (2) 
investigating their association with cognition.  
Method: Plasma and serum BDNF levels and neuropsychological performance were assessed 
in 16 ARMS, 6 first-episode psychosis (FEP), and 11 chronic-schizophrenia (CS) patients. 
Neuropsychological assessment covered intelligence, verbal memory, working memory, 
attention and executive functioning.  
Results: Both plasma and serum BDNF levels were highest in CS, intermediate in FEP and 
lowest in ARMS. Multiple regression analysis revealed a significant positive association of 
plasma BDNF levels with planning ability across all groups.   
Conclusion: The lower peripheral BDNF levels in ARMS compared to FEP and CS might 
point towards an important drop of this neurotrophin prior to the onset of frank psychosis. The 
associations of peripheral BDNF with planning-abilities match previous findings. 
 
Key words: 
BDNF – psychosis – blood – prodromal – neuropsychology  
  
Heitz et al., 2018  BDNF, neurocognition and psychosis 
3 
 
1. Introduction 
 
The presence of cognitive deficits is a consistent finding in patients with psychotic disorders. 
These apply to most cognitive domains including working memory, verbal memory, executive 
function, attention, speed of information processing and visuo-spatial abilities (Fusar-Poli et 
al. 2012; Bora and Murray 2014; Hauser et al. 2017), and are considered to be a core feature 
of these disorders (Szoke et al. 2008).  
Long-term (Agnew-Blais et al. 2015) and cross-sectional studies (Bora et al. 2014) have 
shown that cognitive impairments are present long before the onset of overt psychotic 
symptoms (Riecher-Rössler et al. 2009; Mollon and Reichenberg 2017). However, they do not 
appear to progress after the transition to full-blown psychosis or during the further course of 
the illness (Szoke et al. 2008; Bozikas and Andreou 2011; Irani et al. 2011; Bora and Murray 
2014; Bora et al. 2017). Moreover, among subjects identified as having an at-risk mental state 
for psychosis (ARMS), those with a later transition exhibit more pronounced neurocognitive 
deficits than those who will not go on to develop a psychotic disorder (Studerus et al. 2016; 
Riecher-Rössler and Studerus 2017). However, despite their obvious significance for 
psychosis prediction as well as their importance for functional outcome, the neurobiological 
underpinnings behind the observed impairments remain largely unknown (Ruiz de Azua et al. 
2013). 
Over the last years, the role of brain-derived neurotrophic factor (BDNF) in cognitive 
impairments in patients with psychosis has become a focus of interest. BDNF is the most 
common neurotrophin in the human brain and is involved in the synthesis, differentiation, 
maintenance, and survival of neurons, both in the central and in the peripheral nervous system 
(Kuipers and Bramham 2006). Its role in learning and memory has previously been supported 
by animal (Yamada and Nabeshima 2003; Bekinschtein et al. 2008) as well as human studies 
(for a review see Carlino et al. 2013). In line with these observations, BDNF is highly 
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expressed in hippocampal and prefrontal cortical areas which are crucial for these cognitive 
processes (Conner et al. 1997; Bekinschtein et al. 2008).  
BDNF is also found in the peripheral nervous system and can be assessed in blood serum and 
plasma. Although the exact source of the peripheral BDNF is not yet completely understood, 
animal studies have shown that BDNF can cross the blood-brain barrier (Pan et al. 1998). 
Furthermore, several animal studies have reported positive correlations between serum BDNF 
and BDNF in both the prefrontal cortex and hippocampus (Karege et al. 2002; Sartorius et al. 
2009; Elfving et al. 2010), suggesting there might be a link between peripheral and central 
BDNF. Moreover, Klein and coworkers (2011) reported that blood BDNF concentration 
reflects brain-tissue BDNF level even across species.  
Also, in patients suffering from psychotic disorders altered BDNF levels were found. Post-
mortem studies in patients with schizophrenia point towards decreased cortical BDNF levels, 
especially in memory related brain areas such as the hippocampus (Durany et al. 2001; 
Weickert et al. 2003). 
Peripheral BDNF levels have also been investigated in patients with psychosis. In drug-naïve 
FEP patients, serum BDNF levels have also been reported to positively correlate with BDNF 
levels measured in the cerebrospinal fluid (Pillai et al. 2010). Based on these findings, BDNF 
blood levels are widely used in research as correlates of cortical BDNF. However, so far there 
is no consensus whether plasma or serum BDNF levels are more suitable correlates of cortical 
BDNF levels. While some authors have suggested to use serum as it might provide a more 
reliable measurement (Tsuchimine et al. 2014), others have argued in favour of plasma as it 
might better reflect processes in the central nervous system (Fernandes et al. 2014). 
In patients with psychotic disorders, recent reviews and meta-analyses point towards reduced 
peripheral BDNF levels with peripheral levels being already decreased in FEP patients and 
further declining in chronic and accordingly older patients (Buckley et al. 2011; Green et al. 
2011; Martinotti et al. 2012; Fernandes et al. 2014; Toll and Mane 2015). 
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Until now, several studies have investigated the association between cognitive impairments 
and BDNF in patients with psychosis. The findings of these studies (summarized in 
Supplementary Table 1S) are inconsistent regarding the link of peripheral BDNF levels to 
cognition. The majority of these studies point towards a positive association of certain 
cognitive functions with peripheral BDNF levels (Carlino et al. 2011; Niitsu et al. 2011; 
Zhang XY, Chen da, et al. 2012; Zhang XY, Liang, et al. 2012; Asevedo et al. 2013; Ruiz de 
Azua et al. 2013; Hori et al. 2016; Sun et al. 2016; Hori et al. 2017; Zhang Y et al. 2018). 
However, other studies found mixed results, i.e., positive and negative associations depending 
on the cognitive domain (Niitsu et al. 2014; Xiao et al. 2017). Lastly, other research groups 
did not find any association between these two parameters. A recent meta-analysis concluded 
that there is a small but significant positive association of peripheral BDNF with reasoning 
and problem-solving, and with overall cognitive capacity in patients with schizophrenia 
(Ahmed et al. 2015).  
Despite the strong interest in the prodromal phase of psychosis and the above described 
observed onset of cognitive deficits prior to transition to frank psychosis, no study has 
investigated peripheral BDNF levels in an ARMS sample yet. Therefore, we aimed (1) to 
investigate plasma and serum BDNF levels across different (potential) stages of psychosis, 
including for the first-time ARMS as well as FEP and CS patients, and (2) to examine the 
association of BDNF with neurocognitive performance in these patient groups. 
Based on the above described literature, the following hypotheses were formulated: (1) Both 
plasma and serum BDNF are highest in ARMS, intermediate in FEP, and lowest in CS; (2) 
higher BDNF levels are associated with better cognitive performance in all patient groups. 
 
2. Methods 
2.1. Recruitment and setting 
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FEP and ARMS patients were recruited via the Früherkennung von Psychosen project 
(FePsy; English: early detection of psychosis) within the University of Basel Psychiatric 
Hospital (UPK), Switzerland. ARMS and FEP criteria were assessed using the Basel 
Screening Instrument for Psychosis (BSIP; Riecher-Rössler et al. 2008) which is based on the 
PACE criteria (Yung et al. 1998) and includes parts of the Brief Psychiatric Rating Scale 
(BPRS, expanded version by Lukoff et al., (1986); Ventura et al., (1993)). A detailed 
description of the FePsy study design can be found elsewhere (Riecher-Rössler et al. 2007; 
Riecher-Rössler et al. 2009). Individuals were classified as being in an ARMS if they met one 
of the following inclusion criteria: (1) attenuated or brief limited psychotic symptoms 
according to the criteria by Yung et al. (1998); (2) familial aggregation of psychotic disorders 
in combination with at least 2 further risk factors according to screening instrument in line 
with the criteria by Yung et al. (1998); (3) a minimal amount and combination of certain risk 
factors according to screening instrument by Riecher-Rössler et al. (2007).  FEP patients had 
to fulfil the transition criteria of Yung et al. (1998), namely one of the following symptoms: 
Suspiciousness (BPRS ≥5); Unusual thought content (BPRS ≥5); Hallucinations (BPRS ≥4); 
or Conceptual disorganisation (BPRS ≥5), with the symptom occurring at least several times a 
week and being present for more than one week. Exclusion criteria were age < 18 years, 
insufficient knowledge of German, IQ < 70, previous psychotic episode, antipsychotic 
medication exceeding a cumulative chlorpromazine equivalent (CPE) dose of 2500 mg 
(according to Gardner et al. (2010) and (Leucht et al. 2014)), psychosis clearly due to organic 
brain diseases or substance use, or psychotic symptomatology within a clearly diagnosed 
affective psychosis or borderline personality disorder. 
CS patients were recruited in the forensic department of the UPK and had a diagnosis of 
schizophrenia, paranoid type according to ICD-10 criteria (International Statistical 
Classification of Diseases and Related Health Problems; World Health Organization et al. 
1994). There were no restrictions regarding comorbidities or medication in this group.  
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Only male participants were included in the present study, as BDNF levels can vary between 
the sexes and fluctuate along the menstrual cycle (Begliuomini et al. 2007). Additionally, 
nicotine use was measured in cigarettes per day, as nicotine has previously been found to be 
associated with higher BDNF levels in clinical and non-clinical populations (Bhang et al. 
2010; Zhang XY et al. 2010). All participants gave their written informed consent. The study 
was approved by the committee of North-West and Central Switzerland (Ethikkommission 
Nordwest- und Zentralschweiz (EKNZ)) and was carried out in accordance with the 
declaration of Helsinki.  
 
2.2. BDNF measures 
Peripheral BDNF is mainly stored in blood platelets, while a small part circulates freely. 
Therefore, we assessed total soluble BDNF in serum, which includes BDNF released from 
platelets through clotting, in addition to plasma BDNF levels. For the assessment of BDNF 
levels, a blood sample was drawn between 7 and 9 am after overnight fasting according to a 
standardized protocol, using serum vacutainer tubes (Becton Dickinson) or citrate vacutainer 
tubes (Becton Dickinson). For serum sampling, the tube was inverted 5-6 times gently and 
allowed to stand for 60 min at room temperature. Subsequently, it was centrifuged at 1300xg 
for 10 minutes. Regarding plasma BDNF, poor-platelet-plasma was carefully prepared from 
blood centrifuged at 2000xg for 10 min. All samples were stored in aliquots at −80°C before 
assaying BDNF content. Serum and plasma BDNF levels were assessed with an enzyme-
linked immunosorbent assay (ELISA) kit (Promega BDNF Emax®, Madison, WI, United 
States). Serum samples were appropriately diluted (between 1:100-1:150), while plasma 
samples were used undiluted, and detection of BDNF was carried out in an antibody sandwich 
format as described in the manufacturer’s protocol. The absorbance was measured within 30 
min in a microplate reader set at 450 nm and a correction wavelength set to 690 nm, to 
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determine BDNF concentrations according to the standard curve. All assays were carried out 
in duplicate and means were calculated. 
 
2.3. Neuropsychological assessment 
The following measures were used to cover the cognitive domains of interest:  
 Verbal and non-verbal intelligence: Mehrfachwahl-Wortschatz Test  (MWT-A; Lehrl 
1977) and Leistungsprüfsystem, scale 3 (LPS-3; Horn 1983), respectively  
 Verbal learning and memory: California Verbal Learning Test (CVLT; Delis et al. 
1987) 
 Working memory: 2-back test of the Test of Attentional Performance (TAP; 
Zimmermann and Fimm 1993).  
 Executive functioning: computerized version of the Tower of Hanoi (ToH; Gedika and 
Schöttke 2001) and Go/No-Go task of the TAP (Zimmermann and Fimm 1993)  
 Sustained attention: computerized version of the Continuous Performance Test (CPT-
OX; Rosvold et al. 1956). 
 
2.4. Statistical analyses 
BDNF values were tested for normality and plasma levels were log-transformed to achieve a 
normal distribution. In all subsequently described analyses, the log-transformed plasma values 
were used. BDNF levels were compared between the patient groups (i.e., ARMS, FEP, and 
CS) using a one-way ANOVA, with Bonferroni-corrected post-hoc pairwise comparisons. 
Due to the small sample size, bootstrapping was performed to provide more robust estimates. 
Subsequently, an ANCOVA was carried out including age, CPE and cigarettes per day as 
possible confounding factors. In case of no antipsychotic or nicotine use, a value of 0 was 
used to include these participants in the analysis. 
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A global neuropsychology score comprising all tested domains was created. Furthermore, 
composite scores for each test of the neuropsychological battery were created. Variables for 
which high values indicated worse performance (e.g., reaction times) were inverted prior to 
the z-transformation, so that high values always indicated good performance. The test specific 
composite scores were the averages of the z-transformed performance scores of each test. The 
global cognitive performance score was the average over all z-transformed performance 
scores.  This procedure was used to reduce the number of tests and hence to reduce the risk of 
false positive results due to multiple testing. A description of this procedure can also be found 
in a previous publication of our research group (Rapp et al. 2013). An overview of the test 
variables used to create the composite scores can be found in the appendix (Supplementary 
Table 2S). 
The composite scores were compared between patient groups using a one-way ANOVA, with 
Bonferroni-corrected post-hoc comparisons. Again, bootstrapping was performed due to the 
small sample size. A second group comparison was carried out using an ANCOVA including 
age and CPE as possible confounding factors. 
A Bonferroni-corrected multiple linear regression analysis was performed to assess the 
associations of group, age, years of education, CPE, and the two BDNF measures with each 
neuropsychological composite score.   
Statistical significance was set at alpha ≤ .05. All analyses were carried out using IBM SPSS 
Statistics Version 24 running on Windows 7 Enterprise. 
 
3. Results 
3.1. Sample characteristics  
A total of 33 participants were included in this study: 16 ARMS, 6 FEP and 11 CS patients. 
The CS sample was significantly older than the two other groups and received higher 
antipsychotic dosages (see Table 1). Nicotine use, measured in cigarettes per day, differed 
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significantly between groups, being highest in CS, intermediate in FEP and lowest in ARMS 
individuals. There were no significant group differences regarding years of education. 
 
-Insert Table 1 about here-  
 
3.2. BDNF 
A significant main effect of group was found for both plasma and serum BDNF levels (Table 
2 and Figure 1). Post-hoc pairwise comparisons revealed that serum BDNF was significantly 
lower in ARMS as compared to both other groups (FEP p=.033; CS p<.001), while plasma 
BDNF differed at a significant level only between the ARMS and CS group (p<.001), again 
with lower values in the ARMS group. Plasma BDNF levels differed at a trend level between 
CS and FEP patients (p=.089), being lower in FEP. 
After controlling for age, CPE and cigarettes per day use, serum BDNF values still differed 
significantly between the groups, while the main effect for plasma levels was only significant 
at a trend level (see Table 2). None of the included covariates had a significant effect on 
BDNF parameters. 
 
-Insert Table 2 about here-  
-Insert Figure 1 about here- 
 
3.3. Neuropsychology 
The unadjusted group comparison of the neuropsychological composite scores revealed 
significant differences for the following tests: TAP Go/No-Go and the CVLT (see Table 3). 
Post-hoc pairwise comparisons indicated that the differences in Go/No-Go performance were 
due to poorer performance of the FEP group as compared to the other groups (ARMS p=.004; 
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CS p=.003). The CS group performed worse in the CVLT than the other groups (ARMS 
p=.007; FEP p=.058).  
After including age as covariate, only the main effect for the TAP Go/No-Go remained 
significant (p=.003).  
 
-Insert Table 3 about here- 
 
3.4. Multiple Regression 
The results of the multiple regressions can be found in Table 4. There was a significant 
positive association between plasma BDNF and ToH performance (p=.015) and trend-wise 
significant positive association between plasma BDNF and global cognitive performance 
(p=.071). 
 
-Insert Table 4 about here- 
 
4. Discussion 
In this cross-sectional study we found that plasma and serum BDNF levels differed between 
ARMS, FEP and CS patients, with the highest levels being evident in CS and the lowest in 
ARMS patients. Moreover, higher plasma BDNF levels were significantly associated with 
better ToH performance and at a trend-level with a better global cognitive performance score. 
The observed pattern regarding peripheral BDNF levels contradicts the existing literature 
(Green et al. 2011; Martinotti et al. 2012) as well as our hypothesis of higher BDNF levels in 
ARMS and a decrease over the course of illness. In the present study, serum BDNF levels 
were significantly lower in ARMS patients compared to both other groups, but did not differ 
between FEP and CS patients. Plasma levels were only significantly lower in ARMS 
compared to CS patients. Unfortunately, we were not able to differentiate further between 
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those ARMS patients who transitioned to psychosis and those who did not; therefore, it is not 
possible to interpret the observed pattern regarding transition to psychosis and hence the 
presence of a true prodromal state. Based on the present findings it might be speculated that 
the low peripheral BDNF levels in ARMS patients are associated with the clinical observation 
of a drop in functioning prior to the onset of frank psychosis, including poorer cognitive 
performance which occurs already in the pre-psychotic phase (Riecher-Rössler et al. 2009; 
Bora and Murray 2014). This might imply that the low BDNF levels in ARMS point towards 
pathological processes preceding the actual transition to psychosis. It might be possible that 
during the course of the illness and possibly due to the (pharmacological) treatment of 
psychotic disorders, BDNF levels normalize while cognitive deficits persist, as the latter have 
been suggested by meta-analyses of longitudinal studies (Irani et al. 2011; Bora and Murray 
2014). However, as this is the first study to investigate peripheral BDNF levels in ARMS 
individuals, more research is needed before any firm conclusions can be drawn. 
The factors leading to altered BDNF levels in patients with psychotic disorders are still under 
debate. A recent review by Martinotti et al. (2012) revealed higher peripheral BDNF levels in 
patients suffering from paranoid psychosis compared to other psychotic subtypes. As the CS 
sample in the present study consisted only of patients with such a diagnosis, the higher plasma 
and serum BDNF levels in the CS group might partly be related to this factor. The restriction 
to the paranoid type in our study was made to reduce the variability in this patient group and 
to avoid a potential symptomatic overlap between depressive symptoms and negative 
symptoms, the latter being more present in other types of schizophrenia, since peripheral 
BDNF levels are also altered in patients with depression (Molendijk et al. 2014). 
Contrary to previous studies (Zhang XY et al. 2010; Green et al. 2011) that reported an 
influence of age and nicotine on BDNF levels, these factors were not found to influence 
BDNF in the present study. Regarding medication, the observed lack of effect on BDNF 
levels in our study is in line with the meta-analysis of Green et al. (2011). However, in the 
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more recent meta-analysis of Fernandes et al. (2014) the authors found an increase of BDNF 
in plasma but not in serum after antipsychotic medication, independent of the patient’s 
response to the treatment. In our study, the inclusion of CPE reduced the significance to a 
trend level in plasma but not in serum. It might be speculated that plasma levels react more 
sensitively to antipsychotic treatment, but clearly more research is needed before any firm 
conclusions can be drawn. It should however be mentioned that it is still possible that these 
factors do influence BDNF levels and the present sample was too small to detect this 
association. We can therefore not completely rule out the possibility that the unexpectedly 
higher BDNF levels in the CS group compared to ARMS and FEP patients was influenced by 
the higher medication dosage and longer medication intake with a larger cumulative 
medication dose in the chronic patients. 
Plasma BDNF levels were significantly and positively associated with ToH performance and 
at a trend-level with global cognitive performance, which is in line with our hypothesis and 
with most previous reports investigating the association of peripheral BDNF levels with 
neurocognitive performances. A recent meta-analysis (Ahmed et al. 2015) also indicated a 
positive association of peripheral BDNF levels with neurocognition in patients with 
schizophrenia. In the meta-analysis, higher BDNF levels were associated with better 
performance in reasoning/problem solving and with overall performance across all 
neurocognitive measures.  However, the authors suggested that the association with combined 
neurocognitive measures was driven by the positive association of BDNF levels with 
reasoning/problem solving. A similar pattern could also underlie the present results.  
Due to its exploratory character, the present study suffers from certain limitations. First, the 
small sample size limits statistical power, which might have impeded the detection of group 
differences, and prevented further subgroup analyses. Second, no healthy control or clinical 
control groups were included. Therefore, the specificity of the results for psychosis cannot be 
clarified, especially as altered BDNF levels have also been found in other psychiatric 
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disorders such as depression, bipolar disorder  and anorexia (for a review see Cattaneo et al. 
2016).  Furthermore, BDNF levels in healthy control groups vary considerably across studies 
due to methodological differences (Green et al. 2011), so that the present BDNF levels cannot 
be compared to previous reports. Third, many factors that are known to affect BDNF levels, 
such as antidepressant medication (Polyakova et al. 2015), sleep deprivation (Guzman-Marin 
et al. 2006), stress (Giese et al. 2013), body weight (Pillai et al. 2012), drug consumption 
(D'Souza et al. 2009), or physical exercise (Dinoff et al. 2017) were not assessed in the 
present study. However, we tried to account for the most important confounding factors, 
namely age, years of education, nicotine use and antipsychotics. Fourth, the cross-sectional 
design limits the interpretability of the findings. Longitudinal studies are warranted to 
investigate the time course of BDNF levels across different stages of psychosis.   
Strengths of the present study should also be mentioned, especially the inclusion of innovative 
elements that led to new insights. First, this is the first study to investigate BDNF levels in an 
ARMS sample. The pattern of results indicates that it is vital to further study peripheral 
BDNF levels in this patient population, to promote understanding of the biological 
underpinnings of clinical and cognitive processes preceding the onset of frank psychosis. A 
second strength of this study is the simultaneous analysis of plasma and serum BDNF, 
considering that there is no consensus so far as to which one of the two parameters is a more 
suitable peripheral biomarker. Our results indicate that the free circulating plasma BDNF may 
be more closely associated with cognitive performance and should therefore be considered in 
future investigations.  
In summary, the present study observed lower serum and plasma BDNF levels in ARMS 
patients compared to FEP and CS. This finding, although unexpected at first glance, might 
point towards an important pathological process prior to the onset of full-blown psychosis. 
The observed positive correlation between plasma BDNF and executive functions might 
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provide a link to the well-established cognitive deficits of psychotic disorders, which are 
already present in the at-risk mental state.  
Regarding the potential implications of our study for the field of early detection, the 
surprisingly low peripheral BDNF levels in ARMS patients might be a valuable further 
marker to detect individuals at-risk for psychosis which might, in combination with other 
markers, improve the accuracy of early detection. 
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Table 1: Sample characteristics 
Variable ARMS 
(n=16) 
FEP 
(n=6) 
CS 
(n=11) 
Significance  
Age (years) 24.56 (±5.27) 29.40 (±6.27) 38.38 (±6.63) >.001 
Years of 
education 
12.69 (±2.80) 11.25 (±1.37) 10.91 (±1.26) .211a 
Current use of 
antipsychotics  
(yes/no) 
1/15 4/2 11/0  
CPE 20 (±0) 85.00 (±88.49) 1216.78 
(±987.92) 
.049b 
Current use of 
nicotine  
(yes/no) c 
11/5 4/2 11/0  
Cigarettes per 
dayc 
11.82 (±11.68) 15.00 (±16.58) 31.88 (±14.62) .044a 
 
Note. Mean (± standard deviation); aKruskal-Wallis test, otherwise one-way ANOVA; b 
independent sample t-test; c mean calculated based on those participant with current use 
only; antipsychotic dosage in chlorpromazine equivalents (CPE); at-risk mental state 
(ARMS), first-episode psychosis (FEP), chronic schizophrenia (CS); not applicable (n.a.). 
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Table 2: BDNF level comparison between ARMS, FEP and CS patients 
BDNF (ng 
ml-1) 
ARMS 
(n=16) 
FEP 
(n=6) 
CS 
(n=11) 
Significance  
(ANOVA) 
Significance 
(ANCOVA) c 
Serum 19.11 (±4.67) 24.48 
(±2.40) 
28.08 
(±3.99) 
F(2, 30)= 
15.688; p 
<.001 
F(2, 5)= 
5.322; p=.015 
Plasma  0.30(±0.29)a 0.54(±0.54)a 1.31(±1.06)a F(2, 30)= 
9.835; 
p=.001b 
F(2, 5)= 
2.761; 
p=.090b 
 
Note. Mean (± standard deviation); a non-log transformed values reported; b analysis carried 
out using the plasma log value; c significance after inclusion of age, nicotine use and 
chlorpromazine equivalent (CPE) as covariates; brain-derived neurotrophic factor (BDNF), 
at-risk mental state (ARMS), first-episode psychosis (FEP), chronic schizophrenia (CS). 
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Table 3: Neuropsychological composite score comparison between ARMS, FEP and CS 
Variable ARMS 
(n=13) 
FEP 
(n=5) 
CS 
(n=9) 
Significance 
(ANOVA)  
Significance 
(ANCOVA)a 
IQ 0.12 (±0.78) -0.37 (±0.61) -0.25 (±0.87) F(2, 24)= 
1.027; p=.373 
F(4, 25)= 
1.041; p=.409 
ToH -0.04 (±0.56) -0.66 (±1.11) 0.25 (±0.85) F(2, 24)= 
2.176; p=.135 
F(4, 25)= 
1.226; p=.330 
TAP Go/No-
Go 
0.18 (±0.55) -0.93 (±0.95) 0.29 (±0.33) F(2, 24)= 
8.171; 
p=.002* 
F(4, 25)= 
3.529; 
p=.024* 
TAP WM 0.02 (±0.77) 0.07 (±0.82) -0.05 (±0.43) F(2, 24)= 
0.019; p=.981 
F(4, 25)= 
0.134; p=.968 
CPT 0.12 (±0.47) 0.17 (±0.39) -0.23 (±0.84) F(2, 24)= 
1.027; p=.373 
F(4, 25)= 
0.807; p=.535 
CVLT 0.42 (±0.63) 0.36 (±0.94) -0.71 (±0.84) F(2, 24)= 
6.402; 
p=.006* 
F(4, 25)= 
2.744; p=.056 
Global 0.13 (±0.3) -0.24 (±0.43) -0.08 (±0.38) F(2, 24)= 
1.881; p=.174 
F(4, 25)= 
0.952; p=.454 
  
Note. Mean (± standard deviation); * significant at p<.05; a including age and 
chlorpromazine equivalent as covariate; at-risk mental state (ARMS), first-episode psychosis 
(FEP), chronic schizophrenia (CS). 
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Table 4: Multiple Regression 
Predictor Global IQ ToH TAP 
Go/No-
Go 
TAP 
WM 
CPT CVLT 
Group -.241 
(192) 
-.137 
(.375) 
-.028 
(.392) 
.039 
(.340) 
.422 
(.362) 
-.875 
(.302)° 
-.505 
(.375) 
Age -.289 
(.015) 
.303 
(.030) 
-.328 
(.029) 
.153 
(.027) 
-.434 
(.029) 
.055 
(.024) 
-.343 
(.030) 
Years of 
education 
.073 
(.038) 
.219 
(.074) 
-.153 
(.072) 
.408 
(.066)° 
-.063 
(.071) 
-.124 
(.059) 
.060 
(.072) 
CPE -.116 
(.000) 
-.095 
(.000) 
.023 
(.000) 
.241 
(.000) 
-.381 
(.000) 
.100 
(.000) 
-.116 
(.000) 
Serum BDNF  -.230 
(.022) 
-.148 
(.043) 
-.435 
(.042) 
-.312 
(.040) 
-.376 
(.041) 
.252 
(.036) 
.404 
(.044) 
Plasma BDNF .560 
(.150)° 
-.042  
(.205) 
.804 
(.201)* 
.132 
(.183) 
.298 
(.198) 
.406 
(.163) 
.026 
(.202) 
Note. Standardized coefficient (standard error); * significant at p<.05; ° trend at p<.1 
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Legend to Figure 1: Plasma and Serum BDNF levels in ARMS, FEP and CS 
Note. BDNF = brain-derived neurotrophic factor; ARMS = at-risk mental state for psychosis; FEP = 
first-episode psychosis; CS = chronic schizophrenia. Plasma and serum BDNF values are presented as 
non-log transformed values (ng/ml) with mean and 95% confidence intervals of the mean. 
 
 
